natgillin/translations-raw huggingface dataset:
2 shows the dose-response curves of ST1P01/r-hIL-18BP by KG-1 in vitro bioassay obtained in 10 independent experiments. 
2 prikazuje krivulje odgovora na dozu ST1P01/r-hIL-18BP u in vitro testu KG-1 koji je proveden u 10 neovisnih eksperimenata.
an allyl or propargyl group optionally substituted by one or more halogen atoms or by one or more groups selected from the group consisting of cycloalkyl, hydroxy, (C1-C8) alkoxy, (C1-C8) alkylthio, amino, mono- or dialkylamino, alkoxyalkyl, hydroxycarbonyl and alkoxycarbonyl; and 
alilna ili propargilna skupina, koja može biti supstituirana s jednim ili više atoma halogena ili s jednom ili više skupina koje se bira iz skupine koju čine cikloalkil, hidroksi, (C1-C8) alkoksi, (C1-C8) alkiltio, amino, mono- ili dialkilamino, alkoksialkil, hidroksikarbonil i alkoksikarbonil; i
pyridine optionally substituted by 1 to 3 substituents which are the same or different and selected from a C3-10 cycloalkyl group (preferably cyclopropyl); a C1-6 alkoxy group (preferably ethoxy, isopropoxy); and an optionally substituted C6-14 aryl group (preferably phenyl optionally substituted by 1 to 3 halogen atoms (preferably fluorine)); 
11 naznačen time što prsten A je (1) benzenov prsten po izboru supstituiran s 1 do 4 supstituenata koji su isti ili različiti i odabrani su od: halogenog atoma; skupine C3_19 cikloalkil; skupine C;.4 alkoks1; i skupine C4_14 aril po izboru supstituirane s 1 do 3 halogenih atoma, ili
Preferably the adjuster mandrel includes at one end within the hollow housing a shank having a threaded end and the compression spring defines a hollow, cylindrical shape such that the shank extends through a central bore thereof, the adjuster including a nut that is secured to the adjuster mandrel threadedly received on the said end of the shank. This arrangement is advantageously compact. 
Povoljno je što vreteno podešivača sadrži na jednom kraju unutar šupljeg kućišta osovina, koje ima kraj s navojem, što je kompresijska opruga šupljeg cilindričnog oblika, tako da osovina prolazi kroz njen centralni otvor i što podešivač sadrži navrtku koja je povezana s vretenom podešivača i s navojem na navedenom kraju osovine.
L is substituted at 3-position or 4-position on the benzene ring of the matrix; wherein one end of atom N is connected with the matrix; 
L je supstituiran na poziciji 3 ili 4 na benzenskom prstenu matrice; pri čemu je jedan kraj atoma N povezan sa matricom;
In other embodiments, said formulation is adapted for a once daily transdermal or transmucosal administration to the abdomen (or a portion thereof) of a mammal in need thereof. In yet other embodiments, said formulation is adapted for a once daily transdermal or transmucosal administration to the upper arm (or a portion thereof) of a mammal in need thereof. The present invention further provides a method for administering testosterone to a mammal in need thereof which comprises transdermally administering to a skin or mucosal membrane of a mammal a formulation of the invention. 
Formulacija prema bilo kojem od zahtjeva 1 do 12, naznačena time, da je navedena formulacija prilagođena za transdermalnu ili transmukoznu primjenu u skladu s rasporedom koji je periodičan 1 koji se može prilagoditi jednom dnevno pa do pet puta na dan, jednom tjedno ili dva puta tjedno, pri čemu je poželjno doziranje ono koje se primjenjuje jednom dnevno putem transdermalne ili transmukozne primjene, a poželjno je navedena formulacija prilagođena za doziranje jednom dnevno putem transdermalne ili transmukozne primjene na abdomen ili nadlakticu sisavca kojem je potreban takav tretman. Formulacija prema bilo kojem od zahtjeva 1 do 12, naznačena time, da se upotrebljava kao lijek za transdermalnu primjenu na kožu ili sluznicu sisavca, poželjno muškarca (čovjek).
RF amplifiers; a SIM card. 
RF pojačala; 1 e. < SIM karticu.
A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation within nucleotides 694 to 723 (-260 to -231) of Seq ID No. 1 for high expression under derepression conditions in relation to wild-type AOX1 promoter. 
Promotor alkoholne oksidaze | mutantne Pichia pastoris (AOX1), naznačen time, da je to promotor divljeg tipa Pichia pastoris AOX1 (SEQ ID No.1) koji sadrži najmanje jednu mutaciju unutar nukleotida 170 do 235 (-784 do - 719) od SEQ ID No.1 za visoku ekspresiju pod uvjetima induciranog metanola.
a group represented by: a group represented by: wherein R1 represents a hydrogen atom, an allyl group, or a benzyl group which is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of a C1-6 linear or branched alkyl group, a C1-6 linear or branched alkoxy group, a halogen atom, a nitro group and a cyano group; or a group represented by: 
HN oH skupina koja je predstavljena sa: HR P20170406 T1 rs N Y N OR! u kojoj R' predstavlja atom vodika, alil-skupinu, ili benzil-skupinu koja je nesupstituirana ili je supstituirana s jednim do pet supstituenata odabranih iz skupine koju čine: ravnolančana ili razgranata Ci 4-alkil-skupina, ravnolančana ili razgranata Ci .4-alkoksi-skupina, atom halogena, nitro-skupina i cijano-skupina; ili skupina koja je predstavljena sa: r
A compound according to claim 5 which is 4-(R)-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile in free form, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, naznačen time, da je 4(R)-(6,7-dihidro-5H-pirolo[1,2-climidazol-5-1l)-3-fluoro-benzonitril u slobodnom obliku, ili njegova farmaceutski prihvatljiva sol.
In particular, the invention relates to a compound of formula IIBb 
Farmaceutski sastav koji sadrži spoj formule IIB:
R' and R" together form an acetal protecting group; is an N-containing heterocyclyl or heteroaryl; 
R' 1 R" zajedno tvore acetalnu zaštitnu skupinu; R> je heterociklil ili heteroaril koji sadrži N;
the composition comprises dextran; the composition comprises sodium ions, potassium ions, phosphate ions, chloride ions and polysorbate-80; 
(vii) farmaceutski sastav obuhvaća natrijeve ione, kalijeve ione, fosfatne ione, kloridne ione, i polisorbat 80;
It is known to provide a cap to occlude the nozzle of an inhaler in order to prevent the entrance of dust and dirt, Such caps can be easily lost if they are not retained on the inhaler in some manner. It is possible to attach the cap by means of a flexible strap, which may be made of a rubber material. 
Poznato je da se na inhalator može postaviti zatvarač koji okružuje raspršivač inhalatora da se spriječi ulazak prašine i nečistoća. Takvi se zatvarači lako mogu izgubiti ako na neki način nisu vezani za inhalator. Zatvarač je moguće vezati pomoću elastične vrpce, koja može biti načinjena od gume.
Letermovir according to claim 1, wherein said process for isolating amorphous Letermovir has a drying step in vacuo subsequent to the isolating. 
Letermovir prema zahtjevu 1, pri čemu spomenuti postupak ima naknadni korak sušenja in vacuo.
Compound (1), compound (2), and CXL-1020 were tested for their stability in plasma. 
(Cc) najmanje 7.5 ug spoja sa formulama (1) ili (2)/kg/minuti;
In one embodiment of the present invention, the peptide is a fusion protein which comprises, for example, the 80 N-terminal amino acids of the HLA-DR antigen-associated invariant chain (p33, in the following “Ii”) as derived from the NCBI, GenBank Accession-number X00497 (Strubin, M. et al 1984). 
Peptid u skladu s patentnim zahtjevom 1 ili 2, pri čemu navedeni peptid uključuje nepeptidne veze. Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, pri čemu je navedeni peptid dio fuzioniranog proteina, posebice sadrži N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (1i).
is selected from hydrogen, CORa. COORa, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, and substituted or unsubstituted C4-C12 alkenynyl; 
se bira između vodika, CORa, COORa supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, supstituiranog ili nesupstituiranog C2-C12 alkinila, i supstituiranog ili nesupstituiranog C4-C12 alkeninila;
Figure 1 illustrates the mean exploration time of identical objects in the acquisition phase-T1- following acute administration of Isomer A (3.0-30 mg/kg, p.o) and risperidone (Risp 0.2mg/kg, i.p) in sub-chronic PCP (2mg/kg, i.p twice daily for seven days) and vehicle treated rats. 
Slika 1 prikazuje prosječno vrijeme istraživanja jednakih predmeta u fazi prikupljanja podataka T1 - nakon akutne primjene Izomera A (3.0-30 mg/kg, p.o) 1 risperidona (Risp 0.2mg/kg, 1.p) kod štakora tretiranih sub-kronično s PCP (2mg/kg, i.p dva puta dnevno tijekom tijekom sedam dana) i podlogom.
The composition for the use of claim 7, wherein the heterologous dsRNA is short hairpin RNA (shRNA). 
Pripravak za primjenu prema zahtjevu 7, naznačen time, što je heterologna dsRNK kratka RNK u obliku ukosnice (ShRNA).
For example, inhibition of GnRH stimulated LH release in immature rats may be measured according to the method of Vilchez-Martinez (Endocrinology 96:1130–1134, 1975). 
Kao primjer, inhibiranje otpuštanja LH stimuliranog GnRH-om kod nezrelih štakora može se mjeriti postupkom prema Vilchez-Martinezu (Endocrinology, 96:1130-1134, (1975.)).
A T cell genetically engineered to express a CAR, wherein the CAR comprises (a) an antigen binding domain that is an anti-CD 19 scFv, (b) a costimulatory 4-1BB signaling region, and (c) a CD3 zeta signaling domain, for use in a method for treating cancer that comprises administering said T cell to a human diagnosed with cancer, wherein the anti-CD19 scFv comprises the amino acid sequence of SEQ ID NO:20, and wherein said method generates a population of genetically engineered T cells that persists in the human for at least eight months, nine months, ten months, eleven months, twelve months, two years, or three years after administration, and wherein the human is resistant to at least one chemotherapeutic agent. 
T stanica koja je genetski konstruirana tako da eksprimira CAR, naznačena time što CAR sadrži (a) antigen vezujuću domenu koja je anti-CD19 scFv, (b) kostimulatorno signalno područje 4-IBB, i (c) signalnu domenu CD3 zeta za upotrebu u postupku za liječenje raka koji obuhvaća primjenu navedene T stanice kod čovjeka kojem je dijagnosticiran rak, pri čemu anti-CD19 scFv sadrži aminokiselinsku sekvencu prema SEQ ID NO:20 ili signalnu domenu CD3 zeta sadrži aminokiselinsku sekvencu prema SEQ ID NO:24, 1 pri čemu navedeni postupak stvara populaciju genetski konstruiranih T stanica koje perzistiraju u čovjeku najmanje osam mjeseci, devet mjeseci, deset mjeseci, jedanaest mjeseci, dvanaest mjeseci, dvije godine, ili tri godine nakon primjene, i pri čemu je čovjek otporan na liječenje najmanje jednim kemoterapijskim sredstvom.
In one embodiment of the invention an anti-Adrenomedullin (ADM) antibody or an anti-ADM antibody fragment or anti-ADM non-Ig scaffold is to be used in combination with vasopressors e.g. 
Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema zahtjevu 1, pri čemu spomenuto antitijelo ili fragment ili skela smanjuje vazopresorsku potrebu, npr.
Therapeutic cells for use according to claim 1, said treatment further comprising administering the therapeutic cells to a tissue innervated by the olfactory nerve, wherein the at least one therapeutic cell bypasses the blood-brain barrier to access the damaged central nervous system; and minimizing systemic delivery of the therapeutic cells outside of the central nervous system. 
Terapijske stanice namijenjene upotrebi u skladu s patentnim zahtjevom 1, naznačene time što se navedeno liječenje dodatno sastoji u primjeni terapijskih stanica u tkivo inervirano njušnim živcem, gdje najmanje jedna terapijska stanica zaobilazi krvno-moždanu barijeru kako bi dospijela u oštećeni središnji Živčani sustav; i minimaliziranju sistemskog unosa terapijskih stanica izvan središnjog živčanog sustava.
laying a layer (14) for protecting the inner surface of the bed (11), 
- polaganje sloja (14) za zaštitu unutarnje površine ležaja (11),
The crude product was used in the next reaction without further purification. 
Kruti produkt se koristi za sljedeću reakciju bez daljnjeg pročišćavanja.
The method of claim 2, wherein the pharmaceutical composition maintains at least 95% of the amount of ketorolac or a pharmaceutically acceptable salt thereof after storage for 6 months. 
Postupak pripreme farmaceutskog pripravka koji uključuje kombiniranje ketorolaka ili njegove farmaceutski prihvatljive soli s vodenom otopinom i ekscipijentom, čime se dobiva sastav bilo kojeg od prethodnih zahtjeva.
The composition is lyophilised. Reference 9 in particular purports to disclose the manufacturing process for PROLEUKIN™, including details of expression, recovery, purification, formulation and finishing, but this disclosure is incomplete in several respects. 
Sastav se liofilizira, Referenca 9 osobito otkriva proces proizvodnje za PROLEUKINTY", uključujući detalje ekspresije, regeneracije, pročišćavanja, formuliranja i dovršavanja, ali ovo je otkriće nepotpuno u nekoliko aspekata.
Flexible metal blades 9 are designed to push the top crosspiece of flat plate 8 off the bottom of recess or depression 4c formed in the lateral side of longitudinal blade 4, and so push the wedge-shaped ridge 8a of the top crosspiece outwards of the cylindrical reference surface of mixing member 1, i.e. onto the cylindrical inner surface of bowl 2. 
Fleksibilne metalne trake 9 su dizajnirane da potiskuju gornji poprečni komad ravne ploče 8 od dna udubljenja ili uleknuća 4c, formiranog u bočnoj strani uzdužne lopatice 4 i tako potiskuju klinasto oblikovani greben &a gornjeg poprečnog komada prema vani od cilindrične referentne plohe članka za miješanje 1, t.j. na cilindričnu unutarnju plohu zdjele 2.
Preparation of the compounds of the invention. 
Datum podnošenja europske prijave patenta:
Process for the synthesis of 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one IV, wherein A is a protecting group, which comprises the steps of: 
15. Postupak sinteze 3-A-oksi-estra-1,3,5(10), 15-tetraen-17-on IV, pri čemu je A zaštitna skupina, koji obuhvaća sljedeće korake:
The compound or pharmaceutical composition for use as defined in claim 27, wherein the pain is inflammatory pain, neuropathic pain, pain associated with cancer, pain associated with surgery or pain associated with bone fracture. 
Tvar ili farmaceutski sastav za uporabu definiranu u patentnom zahtjevu 27, pri čemu je bol upalna bol, neuropatska bol, bol povezana s rakom, bol povezana s operativnim zahvatom ili bol povezana s frakturom kostiju.
The management system as claimed in claim 5, wherein said computing means is provided with a processor capable of formulating said data and said additional data. 
Sustav upravljanja prema zahtjevu 5, naznačen time da su navedena računalna sredstva izvedena s procesorom sposobnim za formuliranje navedenih podataka i dodatnih navedenih podataka.
Use of a salt according to any of claims 1-8 in the preparation of a medicament for the treatment of a disease selected from the group consisting of Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and mania in bipolar disorder. 
Uporaba soli prema bilo kojem od zahtjeva 1-8 u pripremi lijeka za liječenje bolesti izabrane iz skupine koja obuhvaća shizofreniju, shizofrenoformni poremećaj, shizoafcktivni poremećaj, deluzije, kratki psihotični poremećaj, podijeljeni psihotični poremećaj i maniju kod bipolarnog poremećaja.
The compound of formula (I') of anyone of claims 5 to 8 for its use according to claim 5, wherein the metabolic syndrome is a complex disease of type 2 diabetes mellitus and obesity. 
Spoj formule (I) iz bilo kojeg od patentnih zahtjeva 5 do 8 za njegovu primjenu prema patentnom zahtjevu 5, gdje je metabolički sindrom kompleksna bolest dijabetes melitusa tipa 2 i pretilosti.
Process according to any of the claims 1 to 5, wherein, during step c), the pH value of the mass being treated is checked and adjusted to a value situated anywhere between 2.6 and 2.9 through the addition, in a shower-like manner as the purée keeps being stirred, of acid substances selected from citric acid, lactic acid, ascorbic acid, hydrochloric acid, sorbic acid, phosphoric acid, and mixtures thereof. 
Postupak prema bilo kojem od zahijeva 1 do 5, naznačen time da se, tijekom koraka c), provjerava pH vrijednost mase koja se obrađuje, te se podešava na vrijednost koja se nalazi između 2.6 1 2.9 tijekom postupka dodavanja, dodavanjem na način poput prskalice dok se kaša miješa, kiselih tvari koje su odabrane od limunske kiseline, mliječne kiseline, askorbinske kiseline, klorovodične kiseline, sorbinske kiseline, fosforne kiseline, te od njihovih smjesa.
Another aspect of the invention relates to a method of treating inflammation (particularly neurogenic inflammation), pain, thermal injury, circulatory shock, diabetes, Reynaud's syndrome, peripheral arterial insufficiency, subarachnoid/cranial hemorrhage, tumor growth, flushing associated with menopause and other conditions the treatment of which can be effected by the antagonism of the CGRP receptor by the administration of pharmaceutical compositions comprising a compound of formula I as defined herein. 
Spoj sukladno patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, za uporabu u postupku liječenja upale, boli, opekline, cirkulatornog šoka, dijabetesa, Reynaudovog sindroma, periferne arterijske insuficijencije, subarahnoidnog/kranijalnog krvarenja, rasta tumora, valunga povezanih sa menopauzom. Spoj sukladno patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, za uporabu u postupku liječenja migrene.
angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, 
(di) - antagonist receptora angiotenzina II ili njegova farmaceutski prihvatljiva sol,
European Patent Application Publication No. 0598359 
Datum podnošenja europske prijave patenta:
The data carrier as claimed in claim 13, wherein it is an identity card, a page of a passport, a credit card or the like. 
. Nosač podataka prema zahtjevu 9, naznačen time da je osobna iskaznica, stranica putovnice, kreditna kartica ili slično.
The pharmaceutical composition of claim 1, comprising droxidopa in combination with tolcapone. 
Farmaceutski sastav, prema zahtjevu 1, naznačen je time da sadrži droksidopu u kombinacijama sa tolkaponom.
A pharmaceutical composition comprising the compound of claim 1 in unit dosage form with at least one pharmaceutically acceptable excipient. A compound as defined in claim 1, for use as an anti-proliferative agent. 
S ne oK Å anac tvar. što je namijenjen upotrebi kao antiproliferativno sredstvo. cnu n spoj u skladu s patentnim zahtjevom 1, u obliku jedinice ži ime t ćen
Structure in accordance with any of the previous claims, in which the said insulating surround includes parts of upright and parts of jamb covered by respective section (34) in metal or plastic material suitable for being left visible. 
Struktura prema bilo kojem prethodnom zahtjevu, naznačena time da navedeno izolacijsko okruženje (12) uključuje dijelove okomitih (10") i dijelove gornjih/donjih horizontalnih strana (10’) koje su prekrivene odgovarajućim profilom (34) od metalnog ili plastičnog materijala koji se može ostaviti vidljivim.
(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone in its racemic or enantiomeric form for use in treatment or prophylaxis of indications involved with oxidative stress induced cell damage. 
(6-hidroksi-2,5,7;8-tetrametikhroman-2-11)(4-(2-hidroksietiDpiperazin-1-yl)metanon, naznačen time, da je u svojem racemičnom ili enantiomernom obliku u svrhu liječenja ili profilakse indikacija vezanih za oštećenje stanica izazvano oksidativnim stresom.
Thus the present application discloses a method for synthesizing N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide and the mesylate salt thereof according to the following steps: Step A: Reacting compound A of the following general formula A* 
PATENTNI ZAHTJEVI 1. Metoda za sintetiziranje N-[S-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)feniljacetamida prema sljedećim koracima: Korak A: reakcija tvari A sljedeće opće formule A*
obtains a first predicted value of pixels of a current prediction unit among the at least one prediction unit by using an average of neighboring pixels of the current prediction unit, and 
određuje jedinicu predviđanja trenutne jedinice kodiranja podjelom trenutne jedinice kodiranja na barem jednu jedinicu predviđanja;
reacting a compound of the formula R-CN (II a), wherein R comprises a protected reactive group, with an azide of formula RIR2MN3 (IIb), and 
(i) reakciju spoja formule R-CN (II a), gdje R sadrži zaštićenu reaktivnu skupinu, s azidom formule R:R2MN (II b), te
A Plastoferrite plate (model M201.1, Maurer magnetics AG, CH-8627 Grüningen) was magnetised in a direction perpendicular to the surface and then engraved on a computer-controlled mechanical engraving station with a geometrical design (two pyramids; see Figure 3a). 
Ploča izrađena od Plastofenita (model M201.1, Maurer magnetics AG, CH-8627 Gruningen) se magnetizira u smjeru okomito na površinu, nakon čega se na računalno nadziranoj mehaničkoj postaji za graviranje na ploču ugravira geometrijski uzorak (dvije piramide; vidi Sliku 3a).
The humanized anti-CD40 antibodies and binding agents can be used in the treatment of a variety of diseases or disorders characterized by the proliferation of cells expressing the CD40 surface antigen. 
Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što je namijenjeno upotrebi u liječenju ili ublažavanju bolesti ili poremećaja kod sisavca.
Process according to claim 3, wherein the amount of calcium present in the final liquid pharmaceutical formulation is less than 5 ppm. Process according to claim 2, wherein the liquid pharmaceutical formulation is prepared from ingredients including chelate powder, water and meglumine, and wherein the amount of calcium in the ingredients used to prepare the final liquid pharmaceutical formulation is less than 50 ppm. 
Postupak prema zahtjevu 8, naznačen time da je količina kalcija u tekućoj farmaceutskoj formulaciji koja se daje pacijentu manja od 50 ppm i time da je količina kalcija u sastojcima koji se koriste za farmaceutsku otopinu u koraku b), odnosno za DOTA prašak, vodi i megluminu, manja od 20 ppm, poželjno manja od 15 ppm.
An isolated antibody that binds human CD134, comprising a light chain variable region (VL) of SEQ ID NO: 98, or having 1, 2 or 3 amino acid substitutions in the VL of SEQ ID NO: 98 and a heavy chain variable region (VH), wherein the VH comprises the amino acid sequence of SEQ ID NO: 134, or having 1, 2 or 3 amino acid substitutions in the VH of SEQ ID NO: 134 or the VH comprises the amino acid sequence of SEQ ID NO: 97, or having 1, 2 or 3 amino acid substitutions in the VH of SEQ ID NO: 97, wherein 
PATENTNI ZAHTJEVI Izolirano protutijelo koje veže humani CD 134, koje sadrži varijabilnu regiju lakog lanca (VL) od SEK ID BR: 98, ili koje ima 1, 2 ili 3 supstituciju aminokiselina u VL-u od SEK ID BR: 98 i varijabilnu regiju teškog lanca (VH), naznačeno time, da VH sadrži sekvence aminokiselina od SEK ID BR: 134, ili ima 1, 2 ili 3 supstituciju aminokiselina u VH od SEK ID BR: 134 ili VH sadrži sekvence aminokiselina od SEK ID BR: 97, ili ima 1, 21li 3 supstituciju aminokiselina u VH od SEK ID BR: 97, naznačeno time, što a.
Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer 
DERIVATI MALEIMIDA, FARMACEUTSKI PRIPRAVCI I POSTUPCI LIJECENJA RAKA